"We Envision Growth Strategies Most Suited
to Your Business"

Non Invasive Prenatal Testing Market to Hit $13.16 bn by 2028; Product Innovations by Companies to Stimulate Growth

August 27, 2021 | Healthcare

The global Non Invasive prenatal testing (NIPT) market size is expected to gain momentum by reaching USD 13.16 billion by 2028 from USD 4.11 billion in 2021. This information is published by Fortune Business Insights in its report, titled “Non Invasive Prenatal Testing (NIPT) Market Size, Share & COVID-19 Impact Analysis, By Product (Instruments, and Consumables & Reagents), Technology (Next Generation Sequencing, Microarray, PCR, and Rolling Circular Amplification), End-User (Hospitals, and Clinical Laboratories) and Regional Forecast, 2021-2028.” The report further observes that the market stood at USD 3.48 billion in 2020 and is projected to exhibit a CAGR of 18.1% between 2021 and 2028.


Illumina Partners Next Generation Genome to Introduce VeriSeq NIPT Solution across Thailand


In May 2021, Illumina, Inc., a leading player in the development of DNA sequencing technologies, announced its partnership with Thailand-based Next Generation Genome Co., Ltd. (NGG) The partnership is aimed at the development and launch of VeriSeq Non Invasive Prenatal Testing Solution v2 in Thailand. According to the companies, the automated in-lab solution NGG to introduce the Qualifi Prenatal Test and be the first-ever laboratory to ensure accurate detection of anomalies that targets assays miss while delivering detailed insights on the health of a pregnant woman. Such initiatives are expected to provide the patients with personalized and timely pregnancy management options that will help to empower their journey through pregnancy.


To get a detailed report summary and research scope of this market, click here:


https://www.fortunebusinessinsights.com/industry-reports/non-invasive-prenatal-testing-market-100998


Continual Product Innovations to Surge Product Demand


In 2019, Progenity, Inc., a leading biotechnology company, introduced Resura Prenatal Test for Monogenic Disease, a customizable NIPT for single-gene disorders. Several companies like Progenity, Inc. focus on the development of advanced screening technologies that are accurate in early detection of genetic disorders in babies. In addition, screening policies adopted by several governments worldwide is expected to bode well for the global Non Invasive prenatal testing market growth during the forecast period. For instance, in 2018, the National Health Service (NHS) announced the implementation of initiatives involving promotions of NIPT solutions in their public health policies.


Contract Signing by Prominent Companies to Propel Market Growth


The global market is experiencing high competition from the players present in it that are focusing on signing lucrative contracts to expand their product portfolio. Moreover, other key players are striving to maintain their presence by focusing on leveraging the market opportunities by following organic and inorganic strategies in the forthcoming years.


Industry Development:



  • March 2020 – YOURGENE HEALTH announced the acquisition of AGX-DPNI, a privately held company based in Versailles. The company sells pharmaceutical and cytogenetic laboratory products in France.


List of the Companies Profiled in the Market



  • Illumina, Inc. (U.S.)

  • YOURGENE HEALTH (U.K.)

  • Natera (U.S.)

  • F. Hoffmann-La Roche Ltd (Switzerland)

  • PerkinElmer Inc. (U.S.)

  • Laboratory Corporation of America (U.S.)

  • Eurofins LifeCodexx GmbH (Germany)

  • Others


Further Report Findings:



  • North America is expected to dominate and hold the largest global Non Invasive prenatal testing market share during the forecast period. This dominance is attributable to the increasing cases of Down Syndrome among newborn babies in countries such as the U.S. The region stood at USD 1.79 billion in 2020.

  • The market in Europe is expected to experience considerable growth during the forecast period. This is owing to the presence of strong reimbursement policies regarding the Non Invasive prenatal testing solutions in the region.



  • Based on the technology, the next-generation sequencing segment held a market share of about 77.8% in terms of revenue during the forecast period. This is due to the growing adoption of next-generation sequencing in identifying the risk of fetal chromosomal anomalies.


Table of Segmentation:


















































  ATTRIBUTE



  DETAILS



Study Period



2017-2028



Base Year



2020



Forecast Period



2021-2028



Historical Period



2017-2019



Unit



Value (USD Billion)



Segmentation



Product; Technology; End User and Geography



By Product




  • Consumables & Reagents

  • Instruments



By Technology


 




  • NGS

  • Microarray

  • PCR

  • Rolling Circular Amplification



By End User




  • Hospitals

  • Clinical Laboratories



By Region




  • North America (By Product; by Technology; by End User and by Country)


    • The U.S. (By Product)

    • Canada (By Product)


  • Europe (By Product; by Technology; by End User and by Country)


    • The U.K. (By Product)

    • Germany (By Product)

    • France (By Product)

    • Italy (By Product)

    • Spain (By Product)

    • Rest of Europe (By Product)




  • Asia Pacific (By Product; by Technology; by End User and by Country)




    • China (By Product)

    • Japan (By Product)

    • India (By Product)

    • Australia (By Product)

    • Southeast Asia (By Product)

    • Rest of Asia Pacific (By Product)


  • Latin America (By Product; by Technology; by End User and by Country)


    • Brazil (By Product)

    • Mexico (By Product)

    • Rest of Latin America (By Product)


  • Middle East & Africa (By Product; by Technology; by End User and by Country)


    • GCC (By Product)

    • South Africa (By Product)

    • Rest of Middle East & Africa (By Product)



Global Non-Invasive Prenatal Testing Market
  • PDF
  • 2022
  • 2019-2021
  • 120

    CHOOSE LICENSE TYPE

  • 4850
    5850
    6850

Our Clients

Lek
Kpmg
Radico
Gallagher
Mitsubishi
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X